Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02567422 · OUTCOME

Potential Drug-drug Interaction

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer · Source last updated 2026-07-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
ug/L
Interval / dispersion
Standard Deviation
Time frame
Up to Day 5

What was measured

The maximum concentration of M6620 in the blood when aprepitant is also given.

Analysis population: Based on samples collected. PK was only collected in the dose escalation phase. PK was not collected for participants in the dose expansion arm.

Groups in this outcome

Dose Level 1

Patients received M6620 (VX-970, berzosertib) 120 mg/m2 by infusion in their arm weekly, cisplatin 40 mg/m2 IV weekly starting a week after M6620, and radiation therapy 70 Gy daily Monday-Friday also starting a week after M6620.

Dose Level 2

Patients received M6620 (VX-970, berzosertib) 160 mg/m2 by infusion in their arm weekly, cisplatin 40 mg/m2 IV weekly starting a week after M6620, and radiation therapy 70 Gy daily Monday-Friday also starting a week after M6620.

Dose Level 3

Patients received M6620 (VX-970, berzosertib) 200 mg/m2 by infusion in their arm weekly, cisplatin 40 mg/m2 IV weekly starting a week after M6620, and radiation therapy 70 Gy daily Monday-Friday also starting a week after M6620.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose Level 15
Dose Level 20
Dose Level 35

Reported measurements

Source class 1
Values in ug/L · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Dose Level 17322.5Not reportedNot reportedNot reported
Dose Level 311491.9Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        2.5
        value
        732
      2. group Id
        OG002
        spread
        1.9
        value
        1149
denoms
  1. counts
    1. group Id
      OG000
      value
      5
    2. group Id
      OG001
      value
      0
    3. group Id
      OG002
      value
      5
    units
    Participants
description
The maximum concentration of M6620 in the blood when aprepitant is also given.
dispersion Type
Standard Deviation
groups
  1. description
    Patients received M6620 (VX-970, berzosertib) 120 mg/m2 by infusion in their arm weekly, cisplatin 40 mg/m2 IV weekly starting a week after M6620, and radiation therapy 70 Gy daily Monday-Friday also starting a week after M6620.
    id
    OG000
    title
    Dose Level 1
  2. description
    Patients received M6620 (VX-970, berzosertib) 160 mg/m2 by infusion in their arm weekly, cisplatin 40 mg/m2 IV weekly starting a week after M6620, and radiation therapy 70 Gy daily Monday-Friday also starting a week after M6620.
    id
    OG001
    title
    Dose Level 2
  3. description
    Patients received M6620 (VX-970, berzosertib) 200 mg/m2 by infusion in their arm weekly, cisplatin 40 mg/m2 IV weekly starting a week after M6620, and radiation therapy 70 Gy daily Monday-Friday also starting a week after M6620.
    id
    OG002
    title
    Dose Level 3
param Type
GEOMETRIC_MEAN
population Description
Based on samples collected. PK was only collected in the dose escalation phase. PK was not collected for participants in the dose expansion arm.
reporting Status
POSTED
time Frame
Up to Day 5
title
Potential Drug-drug Interaction
type
SECONDARY
unit Of Measure
ug/L

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice